Short Daily versus Conventional Hemodialysis Quality of Life: A Cross-Sectional Multicentric Study in Spain

Abstract

Background: End-stage renal disease is a major health problem worldwide nowadays. Although conventional hemodialysis is the most widely used modality, short daily hemodialysis has been proposed as a more physiologic treatment. The objective of this article is to compare the quality of life of patients on each hemodialysis modality. Methods: A multicentric cross-sectional study was performed in 9 Spanish hospitals. Patients treated for at least 3 months with conventional or short daily hemodialysis were included and quality of life measured using the Euroqol-5D quality of life questionnaire. Bayesian models were used for analyzing quality of life results. Results: Ninety-three patients were included, 27 were on daily hemodialysis and 66 on conventional hemodialysis. All models demonstrated a better quality of life for daily hemodialysis versus conventional hemodialysis. Only 14% of the patients on conventional hemodialysis were willing to change to a daily schedule. Conclusions: Short daily hemodialysis shows a better quality of life than conventional hemodialysis with all Bayesian approaches considered.

Relationship Between Nutritional Parameters and Quality of Life in Patients With End-Stage Kidney Disease on In-Centre Haemodialysis in Al-Ahsa, Saudi Arabia

“…Diagnosing and treating these patients is critical since advanced CKD can result in serious complications including cardiovascular disease, end-stage kidney disease (ESKD), and death [ 4 - 6 ]. ESKD is most commonly treated by conventional haemodialysis (HD) [ 7 ]. In the Middle East, the overall combined prevalence of ESKD was calculated as 360 per million individuals.…”

The impact of short daily hemodialysis on anemia and the quality of life in Chinese patients

“…In the majority of trials, it was observed that sDHD improved physical and mental health-related QOL in patients with ESRD ( 2 ,). Vos et al ( 23 ) found that sDHD significantly improved “general health perception”, a single item of the Kidney Disease QOL (KDQoL) questionnaire, as well as the KDQoL dimension scores “physical health” and “patient satisfaction”.…”

“…Hemodialysis patients often have anemia caused by inadequate synthesis of erythropoietin (EPO), and require therapy with exogenous recombinant human erythropoietin (rHuEPO) to maintain recommended hemoglobin levels. Many treatments to improve the anemia and QOL of patients with ESRD have been investigated ( 1 , 2 ). Short daily hemodialysis (sDHD) was first described in 1968 by DePalma et al ( 3 ) and has been widely used ( 4 ).…”

“…Short daily hemodialysis (sDHD) was first described in 1968 by DePalma et al ( 3 ) and has been widely used ( 4 ). In many countries, except for China, sDHD has been reported to be effective in hemodialysis patients ( 2 ,), but there are few reports on its efficacy in managing anemia and QOL in Chinese patients undergoing hemodialysis. Because the practice patterns of hemodialysis and the body weight of patients in China differ from those in other countries, it is uncertain if sDHD could be as effective for Chinese patients undergoing hemodialysis as in other groups.…”